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Background: To assess the impact of incremental modifications of treatment planning and delivery technique, as
well as patient anatomical factors, on late gastrointestinal toxicity using data from the TROG 03.04 RADAR prostate
radiotherapy trial.
Methods: The RADAR trial accrued 813 external beam radiotherapy participants during 2003–2008 from 23 centres.
Following review and archive to a query-able database, digital treatment plans and data describing treatment
technique for 754 patients were available for analysis. Treatment demographics, together with anatomical features,
were assessed using uni- and multivariate regression models against late gastrointestinal toxicity at 18-, 36- and
54-month follow-up. Regression analyses were reviewed in the context of dose-volume data for the rectum and
anal canal.
Results: A multivariate analysis at 36-month follow-up shows that patients planned using a more rigorous dose
calculation algorithm (DCA) was associated with a lower risk of stool frequency (OR: 0.435, CI: 0.242–0.783, corrected
p = 0.04). Patients using laxative as a method of bowel preparation had higher risk of having increased stool frequency
compared to patients with no dietary intervention (OR: 3.639, CI: 1.502–8.818, corrected p = 0.04). Despite higher risks of
toxicities, the anorectum, anal canal and rectum dose-volume histograms (DVH) indicate patients using laxative had
unremarkably different planned dose distributions. Patients planned with a more rigorous DCA had lower median DVH
values between EQD23 = 15 Gy and EQD23 = 35 Gy. Planning target volume (PTV), conformity index, rectal width
and prescription dose were not significant when adjusted for false discovery rate. Number of beams, beam energy,
treatment beam definition, positioning orientation, rectum-PTV separation, rectal length and mean cross sectional
area did not affect the risk of toxicities.
Conclusions: The RADAR study dataset has allowed an assessment of technical modifications on gastrointestinal
toxicity. A number of interesting associations were subsequently found and some factors, previously hypothesised
to influence toxicity, did not demonstrate any significant impact. We recommend trial registries be encouraged to
record technical modifications introduced during the trial in order for more powerful evidence to be gathered
regarding the impact of the interventions.
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Technical modifications in radiotherapy are often incre-
mental, introduced into practice in institutions as evidence
emerges and technological capability materializes. Plan-
ning studies are used widely to quantify the superiority of
the modifications on the basis of planned dose distribu-
tions [1]. Such studies assume a relationship between dose
precision and what is considered a ‘better’ dose distri-
bution and the actual impact the modifications have on
patients.
For example, more rigorous dose calculation algorithms
(DCA) are introduced because of their ability to correct
for tissue heterogeneity [2] while more sophisticated beam
modification devices allow for increased dose conformality
around the target volume, resulting in a lower dose to
surrounding healthy tissue. Although these treatment
modifications are introduced into clinical practice after
careful consideration of their dosimetric consequences,
ambiguity can persist regarding their clinically relevant
consequences.
Due to the incremental and uncritical nature of tech-
nical changes, their clinical impacts are only occasionally
assessed by way of hypothesis via randomised clinical
study of the factors themselves [3-5]. More frequently,
treatment-related morbidities have been examined via
theoretical analysis using data collected during a study
for which such factors comprise covariates [6-9]. These
studies were either single institutional [3,4,6,7] or accru-
ing from a small number of institutions [8]. Few, if any,
have reported the benefits of these incremental advances
in technique in the multicentre, randomised clinical trial
setting.
Randomised controlled trials are typically not powered
to determine the effect of these technical modifications
on toxicity. Secondary analysis does however offer an al-
ternative way to acquire evidence of probable clinical
consequences [10], taking full advantage of the availabil-
ity of such data to understand how treatment decisions
affect outcomes [11]. Long follow-up time associated
with randomised clinical trials may be able to close the
clinical evidence gap introduced by incremental evolu-
tion in radiotherapy, known to be rather rapid. Further-
more, through collaborative efforts, meta-analyses of
similar high quality clinical trial data has the potential to
provide additional evidence to support the gain in clin-
ical efficacy with the introduction of new technology.
The TROG 03.04 trial of Randomised Androgen
Deprivation and RT (RADAR - NCT00193856) principally
examined the impact of duration of androgen suppression
(AS) therapy on intermediate and high-risk prostate
cancer patients [12,13]. All patients had adjuvant RT
and, as part of an extensive technical quality assurance
(QA) program [14-16], considerable data was collected
on treatment technique. With maturity of late toxicityinformation, these data have now been explored for any
significant relationships between treatment planning




The RADAR trial examined the influence of duration of
AS with or without bisphosphonate treatment, adjuvant
with radiotherapy. Data collection, protocol requirements
and QA have been summarised previously [13,15-17].
This trial commenced accrual at a time when many
participating centres were implementing conformal three-
dimensional (3D) treatment technologies and was conse-
quently undertaken under detailed scrutiny of patient
safety and treatment quality.
Of 1071 men accrued to the trial from 23 participating
centres across Australia and New Zealand between 2003
and 2008, 813 had external beam radiotherapy (without
a brachytherapy boost) and, of these, 754 had complete
technical data available for the analysis presented here,
comprising:
– Digital treatment plan export consisting of axial
computed tomography (CT) slices at maximum
5 mm spacing; delineated clinical target volume
(CTV - the prostate for intermediate-risk patients,
and prostate with proximal seminal-vesicles for
high-risk), planning target volume (PTV) for phase 1
treatment to 46 Gy (PTV1 – CTV +1.0 - 1.5 cm
margin, 0.5 – 1.0 cm posterior margin) and
phase 2 boost (PTV2 – CTV +0.0 – 1.0 cm
margin, < 0.5 cm posterior margin) to 66, 70 or
74 Gy; delineated outer rectal wall; 3D dose matrix for
each phase; information on number of beams, beam
energies and collimation method; utilised dose DCA;
conformity index (CI) [18]
– Form-based information on patient, centre and
treatment demographics, setup technique and
dietary interventions.
Factors could be directly extracted, or derived, from
the resulting archived data sets using the plan review
software, ‘SWAN’ (Sir Charles Gairdner Hospital, Nedlands,
WA, Australia) [19]. Several of these require a brief defin-
ition or description.
– Dose calculation algorithm: these have been
categorised as either ‘type-a’ or ‘type-b’
according to the definitions of Fogliata et al. [2].
Briefly, type-a algorithms do not account for
changes in lateral electron transport due to
inhomogeneity whereas type-b algorithms do
account of such changes.
Table 1 GI endpoints, the scoring system, baseline











Proctitis >0 134/713 116/639 83/482
LENT–SOMA [22]
Stool frequency >0 264/716 220/639 168/487
Tenesmus >0 198/716 174/638 116/487
Rectal bleeding >0 134/716 140/639 114/487
CTC v2.0, Common Toxicity Criteria (version 2); LENT-SOMA, Late Effects of
Normal Tissues-Subjective, Objective, Management, Analytic.
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‘MLC’ (if defined by multileaf collimator),
‘collimator’ (if defined by secondary photon jaws
only) or ‘blocks’ (if patient-specific custom-formed
blocks were used).
– Setup orientation: refers to the orientation (prone
or supine) of the patient at the time of planning CT
scan, consistent with that at treatment.
– Rectal dietary intervention: refers to the
intervention in each centre prior to planning CT
and each treatment fraction, broadly categorised as
‘no intervention’, ‘laxative prior to planning CT and
at least first week of treatment’ and ‘bulking agent
with or without dietary instructions’. In all groups,
patients were required to empty their rectum before
planning and treatment.
– PTV-rectum separation: the distance between the
anterior extent of the outer rectal wall and the PTV
at the axial level of the centre-of-mass of the PTV
(which may be negative if the two definitions intersect
at that level).
– 95% isodoses volume: volume, in cm3, of the 95%
isodose for combined physical phase 1 and 2
isodoses.
– Conformity index (CI): Volume enclosed by 95%
isodose surface/PTV [18].
– Rectal distension: the normal distance between the
most anterior and most posterior coronal planes of
the rectum containing points of the outer rectal wall
at the level of the centre-of-mass of the gross
tumour volume.
– Mean rectal cross-sectional area (CSA): obtained
by dividing the total delineated rectum volume by
the number of CT slices defining the cranio-caudal
length of the rectum (see [20])
Toxicity assessment
After treatment, all patients were routinely followed up
in clinic every 3 months for the first 18 months, then
every 6 months up to 5 years post randomisation and
then annually for a further 5 years. GI toxicities were
assessed using two standard toxicity measurement appar-
atus; Common Toxicity Criteria v2.0 [21] for proctitis,
and LENT-SOMA [22] for stool frequency, tenesmus, and
rectal bleeding. Due to the low number of patients report-
ing high level toxicity, the grade cut-point was adjusted to
include patients reporting low level toxicity as shown on
Table 1. Patients with pre-treatment symptoms were ex-
cluded for that particular endpoint. As the cumulative in-
cidence analysis may overestimate the actual toxicity
burden and may have higher level of noise [23,24], the
prevalence was used in the current analysis. The toxicity
prevalence at 18, 36 and 54 months after randomisation
were presumed to be representative of the late toxicity.For the rest of this paper, proctitis (P) at 18-, 36- and
54-month follow-up will abbreviated as P-18, P-36 and
P-54 respectively. Similar convention is used for stool
frequency (SF), tenesmus (T), and rectal bleeding (RB).
Statistical analysis
The impact of treatment planning and delivery factors on
the occurrence of GI toxicity was analysed by uni- and
multivariate analysis. Univariate analysis was performed
for endpoints to determine odds-ratio (OR). Unselected
multivariate logistic regression analysis (with all factors in-
cluded regardless of statistical significance in univariate
analysis) was used to look for the relative contributions of
the factors. Adjustments for potential confounders were
made for age, risk category, body mass index (BMI) and
the year of treatment. Because many variables were in-
cluded in the analysis, the Benjamini & Hochberg false
discovery rate (FDR) adjustment for multiple testing was
performed [25] which is less conservative than the Bonfer-
roni method. Specifically, we apply the Benjamini &
Hochberg adjustment in R to map each p-value to a
FDR-corrected p-value, which can be interpreted as the
probability that the given factor is a false discovery
[26]. FDR-adjusted p-values < 0.05 were considered sta-
tistically significant.
DVH analysis
Each patient’s anorectum was delineated prior to data
submission and archive, and manually reviewed and re-
defined by SR and MK according to the ‘anorectum’ def-
inition from Peeters et al. (defined as outer rectal wall
from the level of the ischial tuberosities until when the
rectum turns horizontally to the sigmoid colon) from
which the inferior 3 cm were defined separately as the
‘anal canal’ and the remaining as the ‘rectum’ [27]. Doses
for individual treatment phases were combined as equiva-
lent dose in EQD23 = 2 Gy [28], and an independent cal-
culation undertaken in SWAN [19] of the anorectum
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volume threshold indices (labelled as V1, V2 …) represent
the relative proportions of anorectum/anal canal/rectum
volume receiving more than a given dose in 1 Gy intervals.
Median anorectum/anal canal/rectum DVH curves were
derived for patient groups defined according to the
significant variable categories or a dichotomisation of
continuous variables about their median. The 95% con-
fidence interval of the respective median volume at
each EQD23 point was derived from 10
4 bootstrap
samples. These DVH curves are not intended to be
studied as one of the variables but rather to detect
whether there are differences in dose distribution as a
result of different treatment planning and delivery fac-
tors used. Comprehensive DVH analysis has been pub-
lished elsewhere [29].
Results
Data and toxicity description
Distributions of investigated parameters are shown in
Table 2. CI (phase 2), 95% isodose volume, and rectal vol-
ume were excluded from analysis because of the strongTable 2 Distributions of investigated factors
Participants
Age 69 ± 7(49–85) years
BMI 27.98 ± 4.12(17.17-45.77) kg/m2
Year commenced EBRT 2004(125); 2005(200); 2006(234); 2007(181);
2008(12)
Risk category Intermediate (464); High (290)
Planning & Delivery
factors
Dose calculation algorithm [2] Type-a (401); Type-b (350)
Patient orientation at set-up Prone (66); Supine (687)
Prescription dose 66Gy (99); 70Gy (423); 74Gy (229)
Treatment beam definition Block/collimator (259); MLC (484)
Beam energy 6MV (96); 10MV (158); 15MV(5); 18MV (493)
Number of beams 3 (89); 4 (396); 5 (155); 6 (110);7 (2)




PTV1 volume 192 ± 65 (30–704) cm3
95% isodose volume 257 ± 104 (60–1425) cm3
Conformity index [18] 1.34 ± 0.26 (0.72 – 2.94)
Rectal cranio-caudal length 9.6 ± 1.3 (5.4 – 13.5) cm
Mean rectal CSA 7.9 ± 3.4 (0.1 – 26.7) cm2
PTV-rectum separation 0.12 ± 0.32 (−2.6 – 3.39) cm
Continuous factors are specified as mean ± standard deviation (range),
categorical factors are specified as category (number of patients). Not all
patients available for all assessments due to missing data, exclusions etc.
Abbreviations: BMI Body mass index, EBRT External beam radiotherapy,
PTV1 Phase 1 planning target volume (PTV), CSA Cross sectional area.correlation (Spearman R > 0.8) to CI (phase 1), PTV and
mean rectal CSA respectively. Table 2 shows the distribu-
tion of patients with and without toxicities for each end-
points at timepoints.
Outcomes analysis
The results of univariate logistic analysis of treatment
planning and delivery factors affecting late effects, with
significant factors highlighted, are shown in Additional
file 1. Some factors, including DCA, number of beams
and beam energy found to be significantly associated
with at least 3 endpoints but none of the factors remain
significant after FDR adjustments. The multivariate results
for significant factors are in Table 3. At 36-month follow-
up post-randomisation, patients planned with type-b DCA
were associated with lower risk of having increased SF-36
(OR: 0.435, CI: 0.242-0.783, FDR-adjusted p = 0.04). At
54-month, a similar association was found albeit weaker
(unadjusted p-value < 0.10). Similar trends towards signifi-
cance were also found between the DCA and RB-36 and
RB-54). Patients using laxatives as a pre-treatment rectal
preparation had higher risk of SF-36 compared to patients
with no rectal dietary intervention (OR: 3.639, CI: 1.505-
8.818, FDR-adjusted p = 0.04). The effect of laxative as a
pre-treatment rectal preparation was also found to show a
trend toward significance for SF-18 and T-18. Planning
target volume (PTV), conformity index, rectal width and
prescription dose were not significant when adjusted for
false discovery rate. However, special attention is given to
PTV. Before adjustment for multiple comparisons [25], in-
creasing PTV is significantly associated with increasing
risk of SF at 18- and 54-month while at 36-month the as-
sociation shows a suggestive trend (p = 0.06). Number of
beams, beam energy, treatment beam definition, position-
ing orientation, rectum-PTV separation, rectal length and
mean cross sectional area did not affect the risk of toxic-
ities in multivariate analysis.
DVH comparisons
Median anorectum, anal canal and rectum DVH curves
for all patients in the study according to the treatment
factors of interests are shown on Figure 1 (i-ix). At lower
doses, it was found that the difference of the median rela-
tive volume of the anorectum receiving between EQD23 =
15 Gy and EQD23 = 35 Gy is significant between plans
using type-a and type-b with maximum difference of 8%
at V25; lower for type-b. However, at higher doses the dif-
ferences were unremarkable. The same is also seen for
anal canal and rectum DVHs. For dietary intervention,
median DVHs were found to be unremarkably different
for patients administered with pre-simulation treatment
laxative compared to those with no dietary intervention or
prepared with a bulking agent. Consistently higher me-
dian volumes were found for patients with PTV ≤median
Table 3 Multivariate analysis examining relationship between treatment factors to late gastrointestinal toxicities
18 months 36 months 54 months
Endpoint Variable P P* OR (CI) Variable P P* OR (CI) Variable P P* OR (CI)
Proctitis Orientation
(prone vs supine)
0.051 NS 2.467 (0.996–6.111) Conformity index
(continuous)
0.032 NS 3.157 (1.102–9.046)
Mean CSA (per cm2) 0.062 NS 0.926 (0.854–1.004)
Rectal bleeding Dose calculation
algorithm
(type-b vs type-a)
0.011 NS 0.479 (0.271–0.847) Dose calculation
algorithm
(type-b vs type-a)
0.055 NS 0.561 (0.311–1.013)
Rectal width
(per cm)
0.026 NS 0.726 (0.548–0.963)
Prescription
dose (per Gy)
0.021 NS 0.876 (1.017–1.158)
PTV (per cm3) 0.061 NS 1.003 (1–1.007)
Stool frequency Rectal intervention
(bulking agent vs
no intervention)
0.049 NS 0.78 (0.436–1.395) Dose calculation
algorithm
(type-b vs type-a)
0.006 0.039 0.435 (0.242–0.783) Dose calculation
algorithm
(type-b vs type-a)




0.053 NS 1.749 (0.801–3.819) Rectal intervention
(laxative vs no
intervention)
0.003 0.039 3.639 (1.502–8.818) Number of beam
(per 1 beam)
0.083 NS 0.692 (0.457–1.049)
PTV (per cm3) 0.022 NS 1.004 (1.001–1.007) PTV (per cm3) 0.059 NS 1.004 (1–1.007) PTV (per cm3) 0.008 NS 1.007 (1.002–1.012)
PTV–rectal
separation (per cm)
0.061 NS 1.84 (0.971–3.486) Conformity index
(continuous)
0.049 NS 0.293 (0.087–0.993)
Tenesmus Number of
beam (per 1 beam)
0.085 NS 0.775 (0.581–1.036)
Rectal intervention
(laxative vs no intervention)
0.072 NS 2.058 (0.971–4.364)
Abbreviations: P p-value, P* False-discovery-rate-adjusted p-value [25], OR (CI) odds ratio (95% confidence interval), CSA Cross sectional area, PTV Planning target volume, NS not significant. Only variables with
















i) DCA- anorectum ii) DCA – anal canal iii) DCA - rectum
iv) rectal dietary intervention - anorectum v) rectal dietary intervention – anal canal vi) rectal dietary intervention - rectum
vii) PTV- anorectum viii) PTV- anal canal ix) PTV - rectum
Figure 1 Median anorectum, anal canal and rectum dose volume histogram (DVH) curves according to the dose calculation algorithm
(DCA), rectal dietary intervention and PTV. The dashed lines are the 95% confidence interval of the respective median derived from 104
bootstrap samples.
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rectum DVHs.
Discussion
In the current study, we report on the treatment plan-
ning, delivery and anatomical factors impacting late GI
toxicities following external beam RT of the prostate.
This study has several unique and interesting features
including the large number of patients with full data
collation and the diversity of treatment technique across
23 institutions. Data was prospectively collected in a
clinical trial setting, monitored by strict quality control
and auditing requirements [16]. As the study was per-
formed in the era of transition to fully 3-dimensional
conformal radiotherapy (3DCRT), some modifications
(e.g. DCA and beam-shaping devices) were captured as
centres transitioned into newer technology. This uniqueopportunity allows the variations to be captured in a
single study enabling analysis on a variety of treatment
factors in the multivariate analysis setting. Addition-
ally, toxicity-specific late endpoints were analysed to
allow a more comprehensive analysis. This is unlike
many other reports which focus on a single specific GI
toxicity (e.g. rectal bleeding [6,30]) or use non-atomised
symptoms grades (e.g. Radiation Therapy Oncology Group
[RTOG] scale [3,4,31]).
We found that in multivariate analysis, several factors
were found to affect the toxicity outcome.
1. Higher odds of stool frequency was found for
patients administered with laxative compared to
patients with no rectal preparatory intervention at
36-month follow-up and potentially at 18-month.
Patients administered with laxative had
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compared to patients who did not receive any
interventions indicating that the decreased toxicity
risk did not originate from differences in the planned
dose distribution.
There are potentially two ways to look at this
observation. First, compared to patients with no
rectal intervention, laxative use helps to minimize
the systematic error due to rectum motion during
pelvic radiotherapy [32,33] but this finding is not
repeated in a randomised study [5]. This careful and
more thorough emptying of rectum by laxative may
also spare the rectal tissue from the benefit of the
blurring effect due to the day-to-day spatial variations.
Second, the intervention may have drug-radiation
synergistic effect to increase damage to the intestinal
villi caused by radiotherapy. Lips et. al found a
trend towards slightly more gastrointestinal toxicity
in the laxative arm than in the placebo arm in a
randomised study [5].
2. Association of type-a DCA used in planning to
increased risks of stool frequency may be related to
the dose distribution difference between the two
DCAs. The disagreements between type-a and type-b
has been proposed to be insignificant in prostate
radiotherapy treatment because tissues in the pelvic
region are generally homogeneous [34]. However, a
treatment planning study comparing the effect of
algorithm on the normal tissue complication
probability (NTCP) model illustrated that the difference
was not insignificant, with the use of type-b resulting
in lower NTCP when the same monitor units were
used [35].
3. We found that patients with smaller PTV had less
risk of gastrointestinal toxicity. This is similar to
previous observations [9,30,31] and is potentially
attributable to the more favourable dose distribution
for patients with smaller PTV.
Several factors found to be significant in previous
studies were not found to be significant in this study, in-
cluding rectum CSA [6,30] and rectal length [6] poten-
tially because of the difference in endpoint definition used.
Prevalence, rather than cumulative incidence, at three late
time points were used in this study to better reflect the ac-
tual toxicity burden and to reduce noise [23,24]. From the
multivariate analysis shown here, it was found that several
factors showed low p-values (p < 0.05, uncorrected) at
a specific time point but were not repeated at other
time points raising the suspicion that it might be due
to data fluctuation or random discovery rather than ac-
tual long term associations. The confidence to report
the associations between dietary intervention and DCA
to toxicity risks, however, was greater as these factorswere also found to have trend towards significance in
other time points. This suggests sustained long-term
associations.
The RADAR trial provided a rich dataset in terms of the
variety of patient treatment and irradiation techniques
used, resulting in diverse combinations of treatment ap-
proaches and dose distributions. All treatments were how-
ever based on 3DCRT and it is important to consider how
the results derived here may be translated to patient treat-
ment with image-guided and intensity-modulated radio-
therapy (IMRT), which are now commonplace. IMRT
produces a more conformal dose distribution to 3DCRT,
enabling higher doses to be prescribed in larger dose per
fraction while maintaining or decreasing the associated
toxicities [7]. Firstly, the rectal preparatory interventions
discussed in this study are still widely used in a more con-
temporary treatment delivery including IMRT [36]. We
have speculated that the elevated risk of toxicity related to
the use of laxative may have an origin largely unrelated to
dosimetry. It is thus expected that the result is applicable
to treatments using IMRT. A comparable effect of using
laxative was also reported in a randomised study with
IMRT as a method of treatment delivery using 77 Gy and
2.2 Gy/fraction regimen [5]. Secondly, the use of many
small beam elements in IMRT to create steep and con-
forming dose gradients may profit more from the use of a
more rigorous DCA [37]. While DCA has not been previ-
ously reported to affect homogenous tissue such as found
in the pelvis [34], conflicting NTCP results have been ob-
served [35]. Finally, better dose sculpting associated with
IMRT delivery may reduce the impact of the PTV on stool
frequency compared to what is observed in this study.
Stool frequency is more strongly associated with dose to
the anal canal [29]. Due to the distance of the anal canal
from the PTV, relevant doses could be reduced by
employing a treatment technique with sharper dose fall-
off. This may in part be compensated by the use of
higher dose prescriptions, often aimed at maintaining
iso-effect in normal tissues. It is unknown what the po-
tential impacts might be of hypofractionation, common
in modern treatments, on the relationships found here.
As the α/β estimate for rectal toxicity is likely higher
than that for prostate cancers, leading to a constant or
lower proportional rectal toxicity rate in hypofractiona-
tion [38], it can be speculated that a less significant rela-
tionship between the treatment factors considered here
and toxicity might be observed.
As an alternative to undertaking a randomised controlled
trial of a specific technical modification, this study has
demonstrated the benefit of careful archival of treatment
demographics to reveal the clinical impact of treatment
modifications. Even when datasets from clinical trials are
not originally powered to assess the effects of these incre-
mental technical modifications, such assessment may offer
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fications typically introduced into practice incremen-
tally and uncritically, derivation of Level III randomised
trial evidence for the impact of such modifications is
unlikely [39]. Consequently, little or no evidence is
available regarding the existence or size of clinical im-
pact of some of the technological modifications studied
here. In most cases, the modifications were introduced
with the immediate aim of improving treatment quality
on the basis of prior successful planning dosimetric
studies [1].
The notion to supplement the evidence from dosimetric
studies with secondary analysis of the data from clinical
trials to determine the clinical consequence is not new.
Clinical trials data is associated with rigorous scrutiny,
consistent adherence to protocol, quality assurance proce-
dures and potentially less noise compared to retrospective
analysis of day-to-day clinical cases making it an appropri-
ate dataset for that purpose [10,16,39]. For example, the
evidence of the benefit of the transition from 3DCRT to
IMRT and image-guided radiotherapy has been success-
fully complemented by secondary analyses of clinical
trials [7,8]. With more trial registries being encouraged
to record the technical modifications introduced, the in-
fluence of technical treatment planning and delivery
factors that may be clinically relevant can be studied
more confidently [39].
The insights obtained in this study are hypothesis-
generating and require independent validation. Specific
limitations in our analysis should be highlighted. The
factors are not independent of each other, with many
factors grouping together due to the technique, experience
and manufacturer-dominated profiles of participating cen-
tres. It should also be noted that the influencing factor of
centre reporting bias cannot be excluded.
Conclusion
The RADAR study dataset has allowed an assessment
of treatment and anatomical factors previously hypothe-
sised to impact on treatment-related GI toxicity. A limited
number of significant associations were subsequently
found which cannot always be explained by the under-
lying planned dosimetry. The ability to undertake this
analysis was facilitated by careful collection of treatment
and demographic data during the undertaking of the trial.
Consequently, trial registries should be encouraged to rec-
ord the technical modifications introduced.Additional file
Additional file 1: Univariate analysis examining relationship between
treatment factors to late gastrointestinal toxicities at 18-, 36- and
54-month follow-up.Abbreviations
RADAR: Randomised androgen deprivation and radiotherapy; DCA: Dose
calculation algorithm; OR: Odds ratio; DVH: Dose-volume histogram;
EQD23: Equivalent dose in 2Gy per fraction using α/β = 3; PTV: Planning
target volume; RT: Radiotherapy; GI: Gastrointestinal; QA: Quality assurance;
CT: Computed tomography; CTV: Clinical target volume; PTV1: Planning
target volume in phase 1; PTV2: Planning target volume in phase 2;
CI: Conformity index; MLC: Multileaf collimator; CSA: Cross sectional area;
FDR: False discovery rate; 3DCRT: 3-Dimensional conformal radiotherapy;
RTOG: Radiation Therapy Oncology Group; NTCP: Normal tissue complication
probability.
Competing interests
The TROG 03.04 trial was financially supported by grant funding from
Australian and New Zealand government, non-government and institutional
sources. Pharmaceutical use and trial logistic support was provided by
Abbott Laboratories and Novartis Pharmaceuticals. No financial benefits were
paid to trial investigators or listed authors.
Authors’ contributions
NY and MAE have made substantial contributions to conception and design
of analysis; NY, MAE, AH, RK, KF, AK, SR, MK and JWD have made substantial
contributions to acquisition of data; NY, MAE, MB to analysis and interpretation
of data. NY has been involved in drafting the manuscript. MAE, AH, JWD, MB
and AK revised it critically for important intellectual content. JWD and DJJ
conceived and participated in the design and coordination of the RADAR trial.
All authors have given final approval of the version to be published.
Acknowledgements
We acknowledge funding from Cancer Australia and the Diagnostics and
Technology Branch of the Australian Government Department of Health and
Ageing (grant 501106), the National Health and Medical Research Council
(grants 300705, 455521, 1006447), the Hunter Medical Research Institute, the
Health Research Council (New Zealand), the University of Newcastle, the
Calvary Mater Newcastle, Abbott Laboratories and Novartis Pharmaceuticals.
We gratefully acknowledge the support of the Sir Charles Gairdner Hospital,
the ‘Elvis’ study team, the contour audit team, participating RADAR centres,
Chantelle Wilcox, Allison Steigler, the Trans-Tasman Radiation Oncology
Group, Jean Ball, Cate Sproston, Sean Hall, Celia Gordon, Scott Chandler,
Scott Williams, Mahesh Kumar, Sean Bydder, Rhonda Coleman, Ben Hooton,
Elizabeth van der Wath.
Author details
1School of Physics, University of Western Australia, Crawley, Western
Australia, Australia. 2School of Health Sciences, National University of
Malaysia, Bangi, Malaysia. 3Department of Radiation Oncology, Sir Charles
Gairdner Hospital, Nedlands, Western Australia, Australia. 4Institute for Health
Research, University of Notre Dame, Fremantle, Western Australia, Australia.
5Department of Physical Sciences, Peter MacCallum Cancer Centre, Victoria,
Australia. 6Sir Peter MacCallum Department of Oncology, University of
Melbourne, Victoria, Australia. 7Sydney Medical School, University of Sydney,
Sydney, New South Wales, Australia. 8School of Surgery, University of
Western Australia, Crawley, Western Australia, Australia. 9School of Medicine
and Public Health, University of Newcastle, Newcastle, New South Wales,
Australia.
Received: 30 September 2014 Accepted: 1 December 2014
References
1. Roelofs E, Persoon L, Qamhiyeh S, Verhaegen F, De Ruysscher D, Scholz M,
Iancu G, Engelsman M, Rasch C, Zijp L, Meerleer GD, Coghe M, Langendijk J,
Schilstra C, Pijls-Johannesma M, Lambin P: Design of and technical
challenges involved in a framework for multicentric radiotherapy
treatment planning studies. Radiother Oncol 2010, 97:567–571.
2. Antonella F, Eugenio V, Dirk A, Carsten B, Alessandro C, Tommy K, Giorgia N,
Luca C: On the dosimetric behaviour of photon dose calculation
algorithms in the presence of simple geometric heterogeneities:
comparison with Monte Carlo calculations. Phys Med Biol 2007, 52:1363.
3. Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque JV,
Levendag PC: Gastro-intestinal and genito-urinary morbidity after 3D
Yahya et al. Radiation Oncology 2014, 9:282 Page 9 of 10
http://www.ro-journal.com/content/9/1/282conformal radiotherapy of prostate cancer: observations of a randomized
trial. Radiother Oncol 2004, 73:1–9.
4. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J,
Horwich A: Comparison of radiation side-effects of conformal and
conventional radiotherapy in prostate cancer: a randomised trial.
Lancet 1999, 353:267–272.
5. Lips IM, van Gils CH, Kotte AN, van Leerdam ME, Franken SP, van der Heide
UA, van Vulpen M: A double-blind placebo-controlled randomized clinical
trial with magnesium oxide to reduce intrafraction prostate motion for
prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012,
83:653–660.
6. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM,
Levegrün S, Burman CM, Fuks Z, Leibel SA, Ling CC: Late rectal toxicity
after conformal radiotherapy of prostate cancer (I): multivariate analysis
and dose–response. Int J Radiat Oncol Biol Phys 2000, 47:103–113.
7. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B,
Coleman J, Lovelock M, Hunt M: Improved clinical outcomes with
high-dose image guided radiotherapy compared with non-IGRT for the
treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol
Phys 2012, 84:125–129.
8. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV: Role of
intensity-modulated radiotherapy in reducing toxicity in dose escalation
for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:685–691.
9. Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, Eble MJ:
Self-assessed bowel toxicity after external beam radiotherapy for
prostate cancer–predictive factors on irritative symptoms, incontinence
and rectal bleeding. Radiat Oncol 2009, 4:36.
10. van Loon J, Grutters J, Macbeth F: Evaluation of novel radiotherapy
technologies: what evidence is needed to assess their clinical and cost
effectiveness, and how should we get it? Lancet Oncol 2012, 13:e169–
e177.
11. Deasy JO, Bentzen SM, Jackson A, Ten Haken RK, Yorke ED, Constine LS,
Sharma A, Marks LB: Improving normal tissue complication probability
models: the need to adopt a “data-pooling” culture. Int J Radiat Oncol
Biol Phys 2010, 76:S151–S154.
12. TROG 03.04 RADAR trial – randomised androgen deprivation and
radiotherapy. 2005, http://clinicaltrials.gov/ct/show/NCT00193856.
13. Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai K-H, Matthews J,
Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt
B, McElduff P: Quality of life in men with locally advanced prostate cancer
treated with leuprorelin and radiotherapy with or without zoledronic
acid (TROG 03.04 RADAR): secondary endpoints from a randomised
phase 3 factorial trial. Lancet Oncol 2012, 13:1260–1270.
14. Ebert MA, Harrison KM, Howlett SJ, Cornes D, Bulsara M, Hamilton CS, Kron
T, Joseph DJ, Denham JW: Dosimetric intercomparison for multicenter
clinical trials using a patient-based anatomic pelvic phantom. Med Phys
2011, 38:5167–5175.
15. Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, Duchesne
G, Murray J, Joseph D: Assuring high quality treatment delivery in clinical
trials - results from the Trans-Tasman Radiation Oncology Group (TROG)
study 03.04 “RADAR” set-up accuracy study. Radiother Oncol 2009,
90:299–306.
16. Kearvell R, Haworth A, Ebert MA, Murray J, Hooton B, Richardson S, Joseph
DJ, Lamb D, Spry NA, Duchesne G, Denham JW: Quality improvements in
prostate radiotherapy: outcomes and impact of comprehensive quality
assurance during the TROG 03.04 ‘RADAR’ trial. J Med Imaging Radiat
Oncol 2013, 57:247–257.
17. Denham JW, Wilcox C, Lamb DS, Spry NA, Duchesne G, Atkinson C,
Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Ebert M, Delahunt B,
McElduff P, Joseph D: Rectal and urinary dysfunction in the TROG 03.04
RADAR trial for locally advanced prostate cancer. Radiother Oncol 2012,
105:184–192.
18. International Commission on Radiation Units and Measurements: ICRU
Report 62. In Prescribing, Recording, and Reporting Photon Beam Therapy
(Supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999.
19. Ebert MA, Haworth A, Kearvell R, Hooton B, Coleman R, Spry N, Bydder S,
Joseph D: Detailed review and analysis of complex radiotherapy clinical
trial planning data: evaluation and initial experience with the SWAN
software system. Radiother Oncol 2008, 86:200–210.
20. Heemsbergen WD, Hoogeman MS, Witte MG, Peeters ST, Incrocci L,
Lebesque JV: Increased risk of biochemical and clinical failure forprostate patients with a large rectum at radiotherapy planning: results
from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat Oncol Biol Phys
2007, 67:1418–1424.
21. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick
B, Morrisintegral M, Rich T, Shipley W, Curran W: Common toxicity criteria:
version 2.0. an improved reference for grading the acute effects of
cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys
2000, 47:13–47.
22. Lent soma scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995,
31:1049–1091 (http://www.ncbi.nlm.nih.gov/pubmed/7713776).
23. Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D,
Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry NA, Tai KH,
Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D'Este C, Bill D:
Delayed rectal and urinary symptomatology in patients treated for
prostate cancer by radiotherapy with or without short term neo-adjuvant
androgen deprivation. Radiother Oncol 2005, 77:117–125.
24. Schmid MP, Potter R, Bombosch V, Sljivic S, Kirisits C, Dorr W, Goldner G:
Late gastrointestinal and urogenital side-effects after radiotherapy–incidence
and prevalence. subgroup-analysis within the prospective Austrian-German
phase II multicenter trial for localized prostate cancer. Radiother Oncol 2012,
104:114–118.
25. Benjamini Y, Hochberg Y: Controlling the false discovery rate - a practical
and powerful approach to multiple testing. J Roy Stat Soc B Met 1995,
57:289–300.
26. R Development Core Team: R: a language and environment for statistical
computing. 2013. R Foundation for Statistical Computing, Vienna,
Austria. 2013. City: ISBN 3-900051-07-0.
27. Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart
MF, Koper PC: Localized volume effects for late rectal and anal toxicity
after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006,
64:1151–1161.
28. Bentzen SM, Dorr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT,
van der Kogel AJ, Wambersie A, Whitmore G: Bioeffect modeling and
equieffective dose concepts in radiation oncology–terminology,
quantities and units. Radiother Oncol 2012, 105:266–268.
29. Ebert MA FK, Haworth A, Gulliford SL, Kennedy A, Joseph DJ, Denham JW:
Gastro-intestinal dose-histogram effects in the context of dose-volume
constrained prostate radiotherapy: an analysis of data from the RADAR
prostate radiotherapy trial. Int J Radiat Oncol Biol Phys in press 9/11/14
30. Munbodh R, Jackson A, Bauer J, Ross Schmidtlein C, Zelefsky MJ: Dosimetric
and anatomic indicators of late rectal toxicity after high-dose intensity
modulated radiation therapy for prostate cancer. Med Phys 2008,
35:2137–2150.
31. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB,
Straube W, Valicenti RK, Cox JD: Long-term toxicity following 3D conformal
radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose
escalation study. Int J Radiat Oncol Biol Phys 2010, 76:14–22.
32. Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, Valdagni R,
Fazio F, Calandrino R: Evidence of limited motion of the prostate by
carefully emptying the rectum as assessed by daily MVCT image guidance
with helical tomotherapy. Int J Radiat Oncol Biol Phys 2008, 71:611–617.
33. Smitsmans MH, Pos FJ, de Bois J, Heemsbergen WD, Sonke JJ, Lebesque JV,
van Herk M: The influence of a dietary protocol on cone beam CT-guided
radiotherapy for prostate cancer patients. Int J Radiat Oncol Biol Phys
2008, 71:1279–1286.
34. Knoos T, Wieslander E, Cozzi L, Brink C, Fogliata A, Albers D, Nystrom H,
Lassen S: Comparison of dose calculation algorithms for treatment
planning in external photon beam therapy for clinical situations.
Phys Med Biol 2006, 51:5785–5807.
35. Bufacchi A, Nardiello B, Capparella R, Begnozzi L: Clinical implications in
the use of the PBC algorithm versus the AAA by comparison of different
NTCP models/parameters. Radiat Oncol 2013, 8:164.
36. McNair HA, Wedlake L, Lips IM, Andreyev J, Van Vulpen M, Dearnaley D: A
systematic review: effectiveness of rectal emptying preparation in
prostate cancer patients. Pract Radiat Oncol 2014, 4:437–447.
37. Davidson SE, Ibbott GS, Prado KL, Dong L, Liao Z, Followill DS: Accuracy of
two heterogeneity dose calculation algorithms for IMRT in treatment
plans designed using an anthropomorphic thorax phantom. Med Phys
2007, 34:1850–1857.
38. Fowler JF: The radiobiology of prostate cancer including new aspects of
fractionated radiotherapy. Acta Oncol 2005, 44:265–276.
Yahya et al. Radiation Oncology 2014, 9:282 Page 10 of 10
http://www.ro-journal.com/content/9/1/28239. Lambin P, Roelofs E, Reymen B, Velazquez ER, Buijsen J, Zegers CM, Carvalho
S, Leijenaar RT, Nalbantov G, Oberije C, Scott Marshall M, Hoebers F, Troost
EG, van Stiphout RG, van Elmpt W, van der Weijden T, Boersma L, Valentini V,
Dekker A: ‘Rapid Learning health care in oncology’ - an approach towards
decision support systems enabling customised radiotherapy. Radiother
Oncol 2013, 109:159–164.
doi:10.1186/s13014-014-0282-7
Cite this article as: Yahya et al.: Impact of treatment planning and
delivery factors on gastrointestinal toxicity: an analysis of data from the
RADAR prostate radiotherapy trial. Radiation Oncology 2014 9:282.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
